Short answer
Dianthus Therapeutics, Inc. /DE/ (DNTH) filed an 8-K current report with the SEC on March 9, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item 2.02 (Results of Operations and Financial Condition). Q4 and full-year 2025 earnings released March 9, 2026: full financials in Exhibit 99.1.
Dianthus Therapeutics, Inc. /DE/ 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 earnings released March 9, 2026: full financials in Exhibit 99.1
- Filing "furnished" not "filed": standard for earnings releases, limits legal liability under Exchange Act
Item 7.01 · Regulation FD Disclosure
- Phase 3 CAPTIVATE trial of claseprubart in CIDP received early "GO" decision following interim responder analysis
- GO decision signals pre-specified efficacy threshold met mid-trial: typically a strong positive catalyst for clinical-stage biotech
- Full results and commentary available via March 9 conference call/webcast at 8:00 am ET; detail in Exhibit 99.2
Item 8.01 · Other Events
- Dianthus filed multiple exhibits on March 9, 2026, including a dedicated data press release and data presentation: signals clinical or preclinical trial results disclosed
- Dual data releases (99.2 + 99.3) suggest structured presentation of study findings, likely for an investor/medical conference or regulatory milestone
- Content of data releases not summarized here: investors should review Exhibits 99.2 and 99.3 directly for efficacy, safety, or biomarker readouts
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Dianthus Therapeutics, Inc. /DE/ 8-K filings
Get the next DNTH 8-K as it lands
Follow DNTH for push alerts, or ask the research agent what this filing means.